{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:46:46Z","timestamp":1790351206235,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["C24\/17\/063"],"award-info":[{"award-number":["C24\/17\/063"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Development of disease\u2010modifying treatments for Huntington's disease (HD) could be aided by the use of imaging biomarkers of disease progression. Positron emission tomography (PET) with\n                      <jats:sup>11<\/jats:sup>\n                      C\u2010UCB\u2010J, a radioligand for the brain\u2010wide presynaptic marker synaptic vesicle protein 2A (SV2A), detects more widespread brain changes in early HD than volumetric magnetic resonance imaging (MRI) and\n                      <jats:sup>18<\/jats:sup>\n                      F\u2010fludeoxyglucose (\n                      <jats:sup>18<\/jats:sup>\n                      F\u2010FDG) PET, but longitudinal\n                      <jats:sup>11<\/jats:sup>\n                      C\u2010UCB\u2010J PET data have not been reported. The aim of this study was to compare the sensitivity of\n                      <jats:sup>11<\/jats:sup>\n                      C\u2010UCB\u2010J PET,\n                      <jats:sup>18<\/jats:sup>\n                      F\u2010FDG PET, and volumetric MRI for detection of longitudinal changes in early HD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Seventeen HD mutation carriers (six premanifest and 11 early manifest) and 13 healthy controls underwent\n                      <jats:sup>11<\/jats:sup>\n                      C\u2010UCB\u2010J PET,\n                      <jats:sup>18<\/jats:sup>\n                      F\u2010FDG PET, and volumetric MRI at baseline (BL) and after 21.4\u2009\u00b1\u20092.7\u2009months (Y2). Within\u2010group and between\u2010group longitudinal clinical and imaging changes were assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The HD group showed significant 2\u2010year worsening of Unified Huntington's Disease Rating Scale motor scores. There was significant longitudinal volume loss within the HD group in caudate (\u22124.5%\u2009\u00b1\u20093.8%), putamen (\u22123.6%\u2009\u00b1\u20093.5%), pallidum (\u22123.0%\u2009\u00b1\u20092.7%), and frontal cortex (\u22122.0%\u2009\u00b1\u20092.1%) (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Within the HD group there was longitudinal loss of putaminal SV2A binding (6.4%\u2009\u00b1\u20098.8%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.01) and putaminal glucose metabolism (\u22122.8%\u2009\u00b1\u20094.4%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.008), but these changes were not significant after correction for multiple comparisons. Premanifest subjects at BL only had significantly lower SV2A binding than controls in basal ganglia structures, but at Y2 additionally had significant SV2A loss in frontal and parietal cortex, indicating spread of SV2A loss from subcortical to cortical regions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Volumetric MRI may be more sensitive than\n                      <jats:sup>11<\/jats:sup>\n                      C\u2010UCB\u2010J PET and\n                      <jats:sup>18<\/jats:sup>\n                      F\u2010FDG PET for detection of 2\u2010year brain changes in early HD. \u00a9 2023 The Authors.\n                      <jats:italic>Movement Disorders<\/jats:italic>\n                      published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mds.29501","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T07:37:39Z","timestamp":1688024259000},"page":"1515-1526","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Longitudinal Imaging of Regional Brain Volumes,\n                    <scp>SV2A,<\/scp>\n                    and Glucose Metabolism In Huntington's Disease"],"prefix":"10.1002","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8497-2314","authenticated-orcid":false,"given":"Aline","family":"Delva","sequence":"first","affiliation":[{"name":"Department of Neurosciences KU Leuven  Leuven Belgium"},{"name":"Department of Neurology University Hospitals Leuven  Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5200-7245","authenticated-orcid":false,"given":"Koen","family":"Van Laere","sequence":"additional","affiliation":[{"name":"Department of Imaging and Pathology KU Leuven  Leuven Belgium"},{"name":"Division of Nuclear Medicine University Hospitals Leuven  Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9758-5062","authenticated-orcid":false,"given":"Wim","family":"Vandenberghe","sequence":"additional","affiliation":[{"name":"Department of Neurosciences KU Leuven  Leuven Belgium"},{"name":"Department of Neurology University Hospitals Leuven  Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.24"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12426"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28855"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70088-7"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.712555"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.2.394"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000132965.14653.D1"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.114.156588"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2014.00078"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A2018"},{"issue":"2","key":"e_1_2_9_12_1","first-page":"215","article-title":"Brain white\u2010matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease","volume":"47","author":"Ciarmiello A","year":"2006","journal-title":"J Nucl Med"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/119.6.2085"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI69411"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7350-7"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm217"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27963"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002391"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012969"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-210475"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4119-8"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2021.117877"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002329"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29148"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2022.06.007"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq5011"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2021.118751"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2014.37"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.11.149"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X17724947"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X20964248"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.1988.91"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.1982.32"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00842779"},{"issue":"7","key":"e_1_2_9_35_1","first-page":"1142","article-title":"Cerebral glucose metabolism during pharmacologic studies: test\u2010retest under placebo conditions","volume":"37","author":"Schmidt ME","year":"1996","journal-title":"J Nucl Med"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X18776820"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-180749"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13339-7"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf6667"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X19879230"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphy.2019.00211"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.29501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:25:31Z","timestamp":1760966731000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.29501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1002\/mds.29501"],"URL":"https:\/\/doi.org\/10.1002\/mds.29501","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]},"assertion":[{"value":"2023-03-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}